Justin Hayes
Family · Morgantown, WVNPI 1740715408
Payments from drug & device makers
Across 713 payments — averaging $17.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$3K
- Abbott$1K
- Lilly USA, LLC$999
- AstraZeneca$938
- Amgen$814
- Boehringer Ingelheim$646
- plus $5K from 32 others
What the payments were for
- Food & beverage$12,381100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 177 | $2,884 |
| Abbott | 87 | $1,314 |
| Lilly USA, LLC | 54 | $999 |
| AstraZeneca(2 entities) | 56 | $938 |
| Amgen | 44 | $814 |
| Boehringer Ingelheim | 41 | $646 |
| Dexcom, Inc. | 33 | $639 |
| Sanofi-aventis U.S. LLC | 37 | $638 |
| Xeris Pharmaceuticals, Inc. | 30 | $593 |
| Insulet Corporation | 18 | $353 |
| AbbVie | 14 | $253 |
| Bayer | 16 | $248 |
| Medtronic | 11 | $207 |
| Zealand Pharma US, Inc. | 13 | $203 |
| Corcept Therapeutics | 7 | $189 |
| Novartis | 9 | $181 |
| Mannkind Corporation | 10 | $157 |
| IBSA Pharma Inc. | 7 | $148 |
| Tandem Diabetes Care, Inc. | 7 | $143 |
| Recordati_rare_diseases_inc. | 5 | $105 |
| Merck | 7 | $98 |
| Sequel Med Tech, LLC | 2 | $86 |
| Amarin Pharma, Inc. | 5 | $80 |
| Rhythm Pharmaceuticals, Inc. | 3 | $73 |
| Ascendis Pharma Endocrinology Inc | 3 | $61 |
| Pfizer | 3 | $54 |
| Kyowa Kirin, Inc. | 2 | $41 |
| Ultragenyx Pharmaceutical Inc. | 2 | $33 |
| Lexicon Pharmaceuticals, Inc. | 1 | $30 |
| Amneal Pharmaceuticals LLC | 1 | $24 |
| Alvogen Inc | 1 | $23 |
| Neurocrine Biosciences, Inc. | 1 | $21 |
| BD | 1 | $19 |
| EUSA Pharma (US) LLC | 1 | $19 |
| GSK | 1 | $19 |
| Ipsen Biopharmaceuticals, Inc | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Cequr Corporation | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$103
How this compares
$12,381 in reported general payments places this provider in the 95th percentile of 1,507 family providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 728 | $1,288,154 |
| OzempicSemaglutide | 370 | $678,977 |
| JardianceEmpagliflozin | 187 | $275,839 |
| Tresiba Flextouch U-200Insulin Degludec | 146 | $212,939 |
| Humalog Kwikpen U-200Insulin Lispro | 49 | $160,579 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 113 | $147,235 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 102 | $135,523 |
| Tresiba Flextouch U-100Insulin Degludec | 189 | $135,417 |
| TrulicityDulaglutide | 65 | $118,843 |
| FarxigaDapagliflozin Propanediol | 80 | $78,737 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 63 | $77,016 |
| Gvoke Hypopen 2-PackGlucagon | 95 | $57,743 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 83 | $52,176 |
| Novolog FlexpenInsulin Aspart | 176 | $51,129 |
| Repatha SureclickEvolocumab | 31 | $34,900 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $999 | $1,413,182809 claims |
| Novo NordiskOzempic, Novolog | $2,884 | $702,133436 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Trijardy Xr | $646 | $422,657300 claims |
| AstraZenecaFarxiga | $938 | $78,73780 claims |
| MerckJanuvia | $98 | $22,72515 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $638 | $20,68412 claims |
| IBSA Pharma Inc.Tirosint | $148 | $4,20917 claims |
| AbbVieSynthroid | $253 | $3,88333 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $24 | $2,220121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,507 family providers in West Virginia.
Other family in Morgantown
- John HuberMorgantown$12K
- Peggy FergusonMorgantown$9K
- Samantha KingMorgantown$7K
- Ashley ComerCharleston$213K
- Dana CruseParkersburg$109K
- Sarah KnightCharleston$99K
- Star RoeBarboursville$55K
- Angela SettleCharleston$51K
- Amber DuncanCross Lanes$44K
- Jennifer FieldsHuntington$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.